Webinar: PARP Inhibitors: What You Need to Know

October 18, 2017 7:32 pm

The following article is provided by The Clearity Foundation to support women with ovarian cancer and their families. Learn more about The Clearity Foundation and the services we provide directly to women as they make treatment decisions and navigate emotional impacts of their diagnosis.

Webinar: PARP Inhibitors: What You Need to Know

Join OCRFA on Monday, Oct. 23rd at 6:00pm ET for a webinar on PARP Inhibitors with Dr. Ursula Matulonis of Dana-Farber Cancer Institute.

There is a great amount of excitement in the ovarian cancer clinical and research communities about the approval of three PARP inhibitors for treatment and maintenance therapy for ovarian cancer. Dr. Matulonis will provide an overview of these new treatments: how they are used now, how they are different from each other, and how they may be used in the future, and will answer your questions.

About the Speaker: Ursula A. Matulonis, MD
Dr. Matulonis, is Medical Director and Disease Center Leader of the Medical Gynecologic Oncology Program at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in the genetic changes in ovarian cancer and how that can lead to rationale drug selection.

Dr. Matulonis is Principal Investigator (PI) of several clinical trials and translational studies for ovarian cancer. She is the PI of a Department of Defense grant on ovarian cancer entitled “Prediction of Response to Therapy and Clinical Outcome Through a Pilot Study of Complete Genetic Assessment of Ovarian Cancer” and a Co-PI on the project “Genetic similarities between serous ovarian cancer and triple negative breast cancer” funded by the Breast Cancer Research Foundation. Dr. Matulonis serves on the National Comprehensive Cancer Network Recommendation and Guideline committee for both ovarian cancer and for the treatment of anemia, the Gynecologic Oncology Group ovarian committee and quality of life committee, the National Cancer Institute Ovarian Cancer Task Force, and is Medical Director and Board Member for the non-profit organization Ovations for the Cure. She is a recipient of the Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, the Zakim Award for patient advocacy and has been named one of Boston’s Best Physicians in Medical Oncology by Boston Magazine.

Date and time: Monday, October 23, 2017 6:00 pm (Eastern Daylight Time)

Duration: 1 hour

Register: Click here

Leave a Reply

Your email address will not be published. Required fields are marked *

Return to Blog Home Return to Clearity Foundation Home